Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

NCT02834507 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease (PD)

Interventions

DRUG: Placebo
DRUG: BIA 3-202
DRUG: Comtan®
DRUG: Sinemet®

Sponsor

Bial - Portela C S.A.